Caris Life Sciences to Showcase Extensive Research with Leading Cancer Centers at ASCO Gastrointestinal Cancers Symposium 2023 Reflecting Its Commitment to Improving Outcomes for Patients
Caris Life Sciences(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced that the company and partners within the Caris Precision Oncology Alliance (POA) will collectively present 18 studies across more than six tumor types at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 19-21, 2023 in San Francisco (Tabletop #70).
“We are proud of the large number of collaborative abstracts accepted for presentation at ASCO GI, demonstrating the power of Caris’ comprehensive molecular profiling and the large-scale collaboration between POA sites,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “The findings represent important observations in a variety of tumors, including rare tumors and new tumor sub-types, which could lead to novel therapeutic approaches and improved outcomes for patients.
“Recommended AI News: A Bad Customer Experience Is Worse Than Shipment Delays, Say 76% Of Americans
“At Caris, our goal is to enable clinicians to make the best treatment choices for their patients, researchers to discover new targets, and the biopharmaceutical industry to develop the next breakthrough medicines,” said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris. “These presentations show how our scientists and partners in the POA are leveraging real-world clinical evidence from over 430,000 lifetime cases in Caris’ unique AI-driven platform to deepen our understanding of cancer. While these discoveries are foundational, they provide key insights into advanced cancer and support developing precision oncology approaches in hardest to treat tumor types to better serve cancer patients.”
Recommended AI News: Blackline Safety Acquires IoT Expert Swift Labs to Expand Connected Worker Portfolio
Caris Life Sciences (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
Recommended AI News: Emerge Partners With TRIPP to Pioneer Tactile Meditation and Human Connection Within the Metaverse
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.